Bringing Reality to a Field of Dreams
This article was originally published in Start Up
Sheryl Skolnick of BancBoston Robertson Stephens givers her advice on how to evaluate eHealth stocks. She's betting that the Internet will change health care in a way that CHINS--the ill-fated attempts to connect health care providers within a community electronically, never could and to that end, she has some words of advice on what is likely to drive successful e-Health companies.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.
While cancer experts are almost giddy with enthusiasm about rapid advances in cancer immunotherapy—in a field not known for euphoria--they are equally pessimistic about market access hurdles as impediments to improved patient care and are seeking manageable approaches to assessing value.